COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Laboratories received new contract manufacturing orders from Nassington and Verisfield for 253,657 units across multiple pharmaceutical products. The orders involve manufacturing of various medicines and oral solutions, deepening existing partnerships but providing no disclosed financial terms or revenue impact.
Actionable Insight
Without financial terms or revenue guidance, the materiality of these orders is unclear. Monitor upcoming quarterly filings for revenue recognition from these orders and for potential follow-on orders that could scale the manufacturing relationship. No immediate trade catalyst.
Key Facts
- Cana Laboratories received orders for 253,657 units from Nassington and Verisfield
- Products include Gritse oral solutions, Fungofort spray, Paco-4 tablets, dexamethasone oral solution, and Fopropt rectal cream
- No financial terms, revenue contribution, or deal value were disclosed
- Orders come from existing partners, suggesting a deepening relationship but not new client wins
- Company's market cap is approximately $13M, making even modest orders potentially notable
Financial Impact
Undisclosed — no dollar value or revenue impact provided in the release
Risk Factors
- No contract value disclosed, making materiality assessment impossible
- Manufacturing orders may be one-time or low-margin
- Forward-looking statements carry typical execution risks for small-cap pharma manufacturers
- Historical calibration shows this report type has a net negative average alpha of -2.79% at T+20 in this segment
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311294 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
3d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2130 (−11.87%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 10, 2026
10d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2130 (−6.62%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2130 (−4.61%) |
|
Jun 8, 2026
12d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 6, 2026
15d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2130 (+7.39%) |
|
Jun 5, 2026
15d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 1, 2026
19d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2130 (−15.81%) |
|
May 26, 2026
25d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2130 (−19.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access